Introduction of Afatinib Intermediate
Afatinib (English: Afatinib), is a kind of innovative anti-cancer targeted therapy, which is a new generation of oral targeted drugs, is the first in the world of irreversible binding to the ErbB family (including four kinds of cancer cells in different epidermal growth factor receptor, such as EGFR, HER2, ErbB3 and ErbB4) anticancer standard the target drug, and more effectively and to block the growth of cancer cells caused by signal, reduce or delay the proliferation of cancer cells. Erlotinib is a daily oral target drug for the treatment of non-small cell lung cancer (NSCLC), which has epidermal growth factor receptor (EGFR) mutated cancer cells. Play a key role in preventing tumor growth and proliferation.
Afatinib Intermediate
(CAS No.:850140-73-7)Product Information:
The action of sunitinib can irreversibly bind to the ErbB family receptor, interrupt the downstream signaling pathway, thereby preventing cancer cell growth and inducing apoptosis (programmed cell death). Therefore, compared with other targeted agents, characteristics of afatinib and ErbB receptors bind irreversibly to provide more lasting and selective, covalent and completely interrupted by the information transmission of cancer cells, leading to cancer treatment benefits unique, the growth of tumor cells have more potential to inhibit the broad categories of its curative effect also more note.
